These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29626377)

  • 21. Varicella-zoster virus infection of a human CD4-positive T-cell line.
    Zerboni L; Sommer M; Ware CF; Arvin AM
    Virology; 2000 May; 270(2):278-85. PubMed ID: 10792986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections.
    Levin MJ
    J Clin Virol; 2014 Dec; 61(4):487-95. PubMed ID: 25453570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A model of Varicella-Zoster reactivation.
    Forde JE; Meeker B
    Math Biosci Eng; 2010 Oct; 7(4):765-77. PubMed ID: 21077706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotyping of Varicella Zoster Virus Clinical Isolates from the Czech Republic.
    Boštíková V; Sleha R; Boštík P
    Cent Eur J Public Health; 2016 Dec; 24(4):331-332. PubMed ID: 28095291
    [No Abstract]   [Full Text] [Related]  

  • 25. Varicella zoster vaccines.
    Creed R; Satyaprakash A; Ravanfar P
    Dermatol Ther; 2009; 22(2):143-9. PubMed ID: 19335725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults.
    Amlie-Lefond C; Gilden D
    J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1561-1569. PubMed ID: 27138380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perspectives on vaccines against varicella-zoster virus infections.
    Gershon AA; Gershon MD
    Curr Top Microbiol Immunol; 2010; 342():359-72. PubMed ID: 20232192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune evasion as a pathogenic mechanism of varicella zoster virus.
    Abendroth A; Arvin AM
    Semin Immunol; 2001 Feb; 13(1):27-39. PubMed ID: 11289797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Varicella-zoster virus neurotropism in SCID mouse-human dorsal root ganglia xenografts.
    Zerboni L; Reichelt M; Arvin A
    Curr Top Microbiol Immunol; 2010; 342():255-76. PubMed ID: 20225014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VZV molecular epidemiology.
    Breuer J
    Curr Top Microbiol Immunol; 2010; 342():15-42. PubMed ID: 20229231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Varicella-zoster virus infection].
    Yoshida M
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():200-4. PubMed ID: 12722214
    [No Abstract]   [Full Text] [Related]  

  • 32. Humoral and cellular immunity to varicella-zoster virus: an overview.
    Arvin AM
    J Infect Dis; 2008 Mar; 197 Suppl 2():S58-60. PubMed ID: 18419410
    [No Abstract]   [Full Text] [Related]  

  • 33. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus.
    Quinlivan ML; Gershon AA; Steinberg SP; Breuer J
    J Infect Dis; 2004 Aug; 190(4):793-6. PubMed ID: 15272408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the treatment of varicella-zoster virus infections.
    Andrei G; Snoeck R
    Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of varicella-zoster virus variation by heteroduplex mobility assay.
    Barrett-Muir W; Hawrami K; Clarke J; Breuer J
    Arch Virol Suppl; 2001; (17):17-25. PubMed ID: 11339546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotypes of varicella-zoster virus wild-type strains in Germany.
    Sauerbrei A; Zell R; Philipps A; Wutzler P
    J Med Virol; 2008 Jun; 80(6):1123-30. PubMed ID: 18428135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical aspects and therapy of Herpes simplex and Varicella-Zoster virus infections in practice].
    Nadal D; Vogt M
    Ther Umsch; 1994 Aug; 51(8):538-44. PubMed ID: 7940410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection and differentiation of wild-type and vaccine mutant varicella-zoster viruses using an Invader Plus method.
    Tang YW; Allawi HT; DeLeon-Carnes M; Li H; Day SP; Schmid D
    J Clin Virol; 2007 Oct; 40(2):129-34. PubMed ID: 17728179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic understanding and control of varicella-zoster virus infection.
    Asano Y
    Vaccine; 2008 Nov; 26(50):6487-90. PubMed ID: 18694794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.